アブストラクト
| Title | II. 化学療法 - 胆膵癌に対する新規化学療法の開発状況 |
|---|---|
| Subtitle | Current Organ Topics : Liver, Pancreas, Biliary Tract Cancer 肝・胆・膵癌 胆膵進行がんの最新の治療展開と今後の展望 |
| Authors | 大場彬博, 奥坂拓志 |
| Authors (kana) | |
| Organization | 国立がん研究センター中央病院 肝胆膵内科 |
| Journal | 癌と化学療法 |
| Volume | 49 |
| Number | 10 |
| Page | 1059-1063 |
| Year/Month | 2022 / 10 |
| Article | 報告 |
| Publisher | 癌と化学療法社 |
| Abstract | 「はじめに」 胆道癌の一次治療では, 10年以上国際的な標準治療であったゲムシタビン(GEM) + シスプラチン(CDDP)療法(GC療法)に免疫チェックポイント阻害薬であるデュルバルマブの上乗せ効果が示され, パラダイムシフトが生じた. また, 二次治療以降でも複数の分子標的薬がその効果を示すなど進歩がみられている. 一方で, 膵癌では一次治療でGEM + ナブパクリタキセル療法(GnP療法)およびFOLFIRINOX療法の, 二次治療ではリポソーム化イリノテカン+フルオロウラシル/ロイコボリン療法(nal-IRI + FF療法)の登場以降, 新たな標準治療の出現はない. また, 分子標的薬としてもオラパリブが生殖細胞系列BRCA遺伝子変異を有する患者に対するプラチナ系レジメン後の維持療法としての有用性を示したのみであり, 免疫チェックポイント阻害薬についてはその有用性は示されていない. |
| Practice | 臨床医学：一般 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に913円(税込) です。
参考文献
- 1) Valle J, Wasan H, Palmer DH, et al : Cisplatin plus gem-citabine versus gemcitabine for biliary tract cancer. N Engl J Med 362(14) : 1273-1281, 2010.
- 2) Morizane C, Okusaka T, Mizusawa J, et al : Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer : the FUGA-BT(JCOG1113) randomized phase III clinical trial. Ann Oncol 30(12) : 1950-1958, 2019.
- 3) Sakai D, Kanai M, Kobayashi S, et al : Randomized phase III study of gemcitabine, cisplatin plus S-1(GCS) ver-sus gemcitabine, cisplatin(GC) for advanced biliary tract cancer(KHBO1401-MITSUBA). Ann Oncol 29(Suppl 8) : viii205, 2018.
- 4) Oh DY, He AR, Qin S, et al : Durvalumab plus gemcita-bine and cisplatin in advanced biliary tract cancer. NEJM Evid : 2022.
- 5) Valle JW, Kelley RK, Furuse J, et al : KEYNOTE-966 trial in progress : pembrolizumab plus gemcitabine and cisplatin for advanced biliary tract cancer. Ann Oncol 31(Suppl 4) : S270-S271, 2020.
残りの17件を表示する
- 6) Lamarca A, Palmer DH, Wasan HS, et al : Second-line FOLFOX chemotherapy versus active symptom con-trol for advanced biliary tract cancer(ABC-06) : a phase 3, open-label, randomised, controlled trial. Lancet Oncol 22(5) : 690-701, 2021.
- 7) Yoo C, Kim KP, Jeong JH, et al : Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after pro-gression on gemcitabine plus cisplatin(NIFTY) : a multicentre, open-label, randomised, phase 2b study. Lancet Oncol 22(11) : 1560-1572, 2021.
- 8) Abou-Alfa GK, Sahai V, Hollebecque A, et al : Pemigati-nib for previously treated, locally advanced or meta-static cholangiocarcinoma : a multicentre, open-label, phase 2 study. Lancet Oncol 21(5) : 671-684, 2020.
- 9) Javle M, Roychowdhury S, Kelley RK, et al : Infigratinib(BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements : mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroen-terol Hepatol 6(10) : 803-815, 2021.
- 10) Abou-Alfa GK, Macarulla T, Javle MM, et al : Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangio-carcinoma(ClarIDHy) : a multicentre, randomised, dou-ble-blind, placebo-controlled, phase 3 study. Lancet Oncol 21(6) : 796-807, 2020.
- 11) Subbiah V, Lassen U, Elez E, et al : Dabrafenib plus tra-metinib in patients with BRAFV600E-mutated biliary tract cancer(ROAR) : a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol 21(9) : 1234-1243, 2020.
- 12) Javle M, Borad MJ, Azad NS, et al : Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer(MyPathway) : a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol 22(9) : 1290-1300, 2021.
- 13) Ohba A, Morizane C, Ueno M, et al : Multicenter phase II trial of trastuzumab deruxtecan for HER2-positive unresectable or recurrent biliary tract cancer : HERB trial. Future Oncol 18(19) : 2351-2360, 2022.
- 14) Ohba A, Morizane C, Kawamoto Y, et al : Trastuzumab deruxtecan(T-DXd ; DS-8201) in patients(pts) with HER2-expressing unresectable or recurrent biliary tract cancer(BTC) : an investigator-initiated multi-center phase 2 study(HERB trial). J Clin Oncol 40(16s) : abstr 4006, 2022.
- 15) Conroy T, Desseigne F, Ychou M, et al : FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364(19) : 1817-1825, 2011.
- 16) Okusaka T, Ikeda M, Fukutomi A, et al : Phase II study of FOLFIRINOX for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Sci 105(10) : 1321-1326, 2014.
- 17) Ozaka M, Ishii H, Sato T, et al : A phase II study of mod-ified FOLFIRINOX for chemotherapy-naive patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 81(6) : 1017-1023, 2018.
- 18) Hoff DDV, Ervin T, Arena FP, et al : Increased survival in pancreatic cancer with nab-paclitaxel plus gemcit-abine. N Engl J Med 369(18) : 1691-1703, 2013.
- 19) Ueno H, Ikeda M, Ueno M, et al : Phase I/II study of nab-paclitaxel plus gemcitabine for chemotherapy-naive Japanese patients with metastatic pancreatic cancer. Cancer Chemother Pharmacol 77(3) : 595-603, 2016.
- 20) Ohba A, Ozaka M, Mizusawa J, et al : Randomized multi-center phase II/III study of gemcitabine plus nab-pa-clitaxel or modified FOLFIRINOX or S-IROX in pa-tients with metastatic or recurrent pancreatic cancer(JCOG1611, GENERATE). J Clin Oncol 40(4s) : TPS627, 2022.
- 21) Wang-Gillam A, Li CP, Bodoky G, et al : Nanoliposomal irinotecan with fluorouracil and folinic acid in meta-static pancreatic cancer after previous gemcitabine-based therapy(NAPOLI-1) : a global, randomised, open-label, phase 3 trial. Lancet 387(10018) : 545-557, 2016.
- 22) Golan T, Hammel P, Reni M, et al : Maintenance olaparib for germline BRCA-mutated metastatic pancreatic can-cer. N Engl J Med 381(4) : 317-327, 2019.
